GLP Compliant EPL operates in full GLP compliance, signaling strong quality controls and reliability in toxicologic pathology services, which can reassure potential customers in regulated preclinical testing and attract sponsors seeking compliant CRO partners.

Integrated Capabilities With EPL core histopathology services complemented by Aclairo’s toxicology, pharmacology, DMPK and clinical pharmacology support, there is a compelling cross-sell opportunity to existing clients and a clear upsell path for integrated preclinical programs.

Comprehensive Services Offerings include histology, immunohistochemistry, electron microscopy, onsite necropsy, digital morphometry, and pathology consultations, enabling EPL to position as a one-stop partner for end-to-end preclinical pathology and related analyses.

Global Quality Signals International recognition for meeting scientific community needs and on-time delivery highlights reliability and global capability, which can be leveraged to win new programs from larger R&D organizations or multi-site trials seeking consistent partners.

Revenue Focus Current revenue range ($25M–$50M) coupled with mid-size employee base suggests scalable growth opportunities through expanded service packages, retainer-like engagements, and targeted marketing to mid-to-large biotech and pharma clients seeking robust CRO partnerships.